4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degenerationeye disorder, macular degeneration, retinal degeneration, retinal disorderRecruitingPhase 1 / Phase 22026-10-09NCT07587515
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEDiabetic Macular Edema (DME)Active, not recruitingPhase 2 / Phase 32026-09-30NCT06571045
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVOEmbolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorderRecruitingPhase 22026-09-04NCT07205887
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEDiabetic Macular Edema (DME)Active, not recruitingPhase 2 / Phase 32026-08-20NCT06957080